The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| E-Paper
Search
+

After a dream listing, is it just a pause for Rossari Biotech, or there is more to it?

After a dream listing, is it just a pause for Rossari Biotech, or there is more to it?
After a dream listing, is it just a pause for Rossari Biotech, or there is more to it?
Arun Kejriwal said that investors across categories who were allotted Rossari Biotech shares seem to have opted for listing gains.

SynopsisThe stock rallied as much as 89 per cent to Rs 804 on listing day from the offer price of Rs 425. It currently trades at Rs 715, down 11 per cent from its peak.

Mumbai: The newest Dalal Street entrant Rossari Biotech had a picture-perfect listing last month, however, the subsequent stock trajectory shows that it may have run up too much and too soon, making valuations expensive.The stock rallied as much as 89 per cent to Rs 804 on listing day from the offer price of Rs 425. It currently trades at Rs 715, down 11 per cent from its peak.The initial public offering (IPO), sold in the price band of Rs
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

To Read the Full Story, Become an ET Prime Member

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Access the exclusive Economic Times stories, Editorial and Expert opinion

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times